This paper is only available as a PDF. To read, Please Download here.
Translational regulation of mRNA permeates nociception. The identities of transcripts
subject to translational control are almost entirely unknown. To address this problem,
we examine the landscape of nascent translation in DRG neurons treated with inflammatory
mediators using ribosome profiling. We identify and validate two targets, the immediate
early genes Arc and Fos, as targets of induced translation. Mechanistically, we demonstrate
that the ribosomal protein S6 kinase (S6K1) is required for their biosynthesis. Pharmacologic
blockade of either S6K1 or Fos attenuates mechanical and thermal hyperalgesia triggered
by inflammatory stimuli. Genetic disruption of Arc did not alter pain associated behaviors.
However, Arc deficient mice display exaggerated paw temperatures and vasodilation
in response to an inflammatory challenge. Since Arc has recently been shown to be
released from neurons in extracellular vesicles, we asked if intercellular Arc signaling
regulates the inflammatory response in skin. We found that the excessive thermal responses
and vasodilation observed in Arc defective mice are rescued by injection of Arc-containing
extracellular vesicles into the skin. Collectively, our results suggest that activity-dependent
translation in the DRG supports at least two critical functions: neurogenic inflammation
(via Arc) and nociception (via Fos).
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The Journal of PainAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2021 Published by Elsevier Inc.
